| Today's Stocks Driving Success For The Health Care Sector 12:17pm / TheStreet.com | Merck Faces Off Against Bristol-Meyers' Yervoy Dec 02 / MotleyFool.com |
| Zoetis Stock: 3 Key Investing Lessons from 2013 10:05am / MotleyFool.com | Merck's Noxafil Tablets Approved by the FDA - Analyst Blog Nov 29 / Zacks.com |
| What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Dru... 9:01am / MotleyFool.com | Buy Today: Merck & Co Inc's Buy Recommendation Reiterated Nov 29 / TheStreet.com |
| Letter from Lex: giving up investor fight 8:17am / FT.com | Johnson & Johnson Stock: 3 Things to Know Before 2014 Nov 29 / MotleyFool.com |
| Frontrunning: December 6 8:10am / Investing Channel | Will This Top Dow Health-Care Stock Stay Healthy in 2014? Nov 28 / MotleyFool.com |
| Soaring Hepatitis C Drug Prices Make Cures Costly Dec 05 / MotleyFool.com | Keep An Eye On GW, Johnson & Johnson, Durata, and Merck Today Nov 27 / MotleyFool.com |
| Merck & Co Inc (MRK): Today's Featured Drugs Laggard Dec 05 / TheStreet.com | Can Zoetis Beat Its Big Pharma Competition? Nov 26 / MotleyFool.com |
| The Deal: Merck Stakes $3 Billion on Gadget Growth Dec 05 / TheStreet.com | Novo Nordisk's Biggest Strength and Weakness Nov 26 / MotleyFool.com |
| Merck KGaA: chemical weapon Dec 05 / FT.com | Merck Gets FDA Approval for Noxafil Tablets, Increases Dividend Nov 26 / MotleyFool.com |
| AstraZeneca Eyes Forest Labs as Shares Rise Dec 04 / MotleyFool.com | Is BioMarin's Vimizim Grabbing Suitors Attention? Nov 26 / MotleyFool.com |
| Biotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And M... Dec 04 / TheStreet.com | Johnson & Johnson Wins Hep C Battle, but War Doesn't Look Good Nov 25 / MotleyFool.com |
| Can Veeva Systems' Partnership With Salesforce.com Lift Its Earnings? Dec 03 / MotleyFool.com | Stock Market News for November 25, 2013 - Market News Nov 25 / Zacks.com |
| Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews Dec 03 / Zacks.com | FDA to Amarin: No Appeal for You Nov 22 / MotleyFool.com |
| Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook Dec 03 / Zacks.com | Big drugmakers such as Novartis turn from expansion to divestment Nov 19 / FT.com |
| Orbimed Advisors Discloses 33.5% stake in Relypsa Inc (RLYP) Dec 03 / Investing Channel | Drug manufacturers seek to expand the range of treatments Nov 13 / FT.com |
| Forest Labs Up on Strategic Initiatives - Analyst Blog Dec 03 / Zacks.com | Merck signs cancer drug research deal with China's BeiGene Nov 13 / FT.com |
| Can Merck Sustain 2013's Healthy Climb in the New Year? Dec 03 / MotleyFool.com | Highlights from this week's Investors Chronicle Nov 08 / FT.com |
| Why Olin, Forest Laboratories, and ProShares UltraShort Silver Soared Today Dec 02 / MotleyFool.com | NHS drugs bill 'frozen' in return for treatment pledge Nov 06 / FT.com |
| Today's Momo Momentum Stock To Watch: Merck (MRK) Dec 02 / TheStreet.com | |
+0.58 / +1.19%